Other Keap1 antagonists include the naturally occurring isothiocyanate sulforaphane [41], and the compound Tecifidera (BG-12/dimethyl fumarate; Biogen Idec) which has recently been approved by the FDA for the treatment of multiple sclerosis, and believed to operate (at least in part) via Keap1-mediated activation of the Nrf2 pathway [42]. Here, KEAP1 is linked to multiple sclerosis.